ALX-0061: Phase II started

Ablynx began a double-blind, placebo-controlled, international Phase II trial to compare 3 dose levels of subcutaneous ALX-0061 every 2 or 4 weeks for 46 weeks in about 300 patients. In 2013, Ablynx a...